These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 15958534)

  • 21. Pamidronate decreases tumor-induced osteoclastogenesis in osteopetrotic mice.
    Clohisy DR; O' Keefe PF; Ramnaraine ML
    J Orthop Res; 2001 Jul; 19(4):554-8. PubMed ID: 11518261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bisphosphonates: structure-activity relations from a clinical perspective.
    Papapoulos SE
    Medicina (B Aires); 1997; 57 Suppl 1():61-4. PubMed ID: 9567357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Properties of bisphosphonates in the 13762 rat mammary carcinoma model of tumor-induced bone resorption.
    Alvarez E; Westmore M; Galvin RJ; Clapp CL; Considine EL; Smith SJ; Keyes K; Iversen PW; Delafuente DM; Sulaimon S; Zambrano C; Ma L; Sato M; Martin TJ; Teicher BA; Galbreath EJ
    Clin Cancer Res; 2003 Nov; 9(15):5705-13. PubMed ID: 14654555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The application advances of bisphosphonates in bone metastasis].
    Liang P
    Zhongguo Gu Shang; 2008 Jun; 21(6):480-2. PubMed ID: 19108448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells.
    Merrell MA; Wakchoure S; Lehenkari PP; Harris KW; Selander KS
    Eur J Pharmacol; 2007 Sep; 570(1-3):27-37. PubMed ID: 17640631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiresorptive dose-response relationships across three generations of bisphosphonates.
    Sietsema WK; Ebetino FH; Salvagno AM; Bevan JA
    Drugs Exp Clin Res; 1989; 15(9):389-96. PubMed ID: 2630251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploring the anti-tumour activity of bisphosphonates in early breast cancer.
    Winter MC; Holen I; Coleman RE
    Cancer Treat Rev; 2008 Aug; 34(5):453-75. PubMed ID: 18423992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel bone-targeted strategies in oncology.
    Vallet S; Smith MR; Raje N
    Clin Cancer Res; 2010 Aug; 16(16):4084-93. PubMed ID: 20643782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maxilla osseus sequestre and oral exposure: effects of the treatment of multiple myeloma with bisphosphonates.
    Lobato JV; Rodrigues JM; Cavaleiro MV; Lobato JM; Xavier L; Santos JD; Maurício AC
    Acta Med Port; 2007; 20(2):185-92. PubMed ID: 17868526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New results from the use of bisphosphonates in cancer patients.
    Coleman R; Gnant M
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):213-8. PubMed ID: 19561507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alendronate inhibits proliferation and invasion of human epidermoid carcinoma cells in vitro.
    Muller S; Migianu E; Lecouvey M; Kraemer M; Oudar O
    Anticancer Res; 2005; 25(4):2655-60. PubMed ID: 16080508
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bisphosphonates in cancer therapy.
    Green JR
    Curr Opin Oncol; 2002 Nov; 14(6):609-15. PubMed ID: 12409650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro and in vivo antitumor effects of bisphosphonates.
    Clézardin P; Fournier P; Boissier S; Peyruchaud O
    Curr Med Chem; 2003 Jan; 10(2):173-80. PubMed ID: 12570716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model.
    Yang M; Burton DW; Geller J; Hillegonds DJ; Hastings RH; Deftos LJ; Hoffman RM
    Clin Cancer Res; 2006 Apr; 12(8):2602-6. PubMed ID: 16638872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer.
    Miwa S; Mizokami A; Keller ET; Taichman R; Zhang J; Namiki M
    Cancer Res; 2005 Oct; 65(19):8818-25. PubMed ID: 16204052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis.
    Green JR; Clézardin P
    Am J Clin Oncol; 2002 Dec; 25(6 Suppl 1):S3-9. PubMed ID: 12562045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bisphosphonates and Cancer: A Relationship Beyond the Antiresorptive Effects.
    Teixeira S; Branco L; Fernandes MH; Costa-Rodrigues J
    Mini Rev Med Chem; 2019; 19(12):988-998. PubMed ID: 31020940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-tumour activity of zoledronic acid.
    Clézardin P
    Cancer Treat Rev; 2005; 31 Suppl 3():1-8. PubMed ID: 16225995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging strategies in bone health management for the adjuvant patient.
    Coleman RE
    Semin Oncol; 2007 Dec; 34(6 Suppl 4):S11-6. PubMed ID: 18068485
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bisphosphonate actions on cancer.
    Yoneda T; Hashimoto N; Hiraga T
    Calcif Tissue Int; 2003 Oct; 73(4):315-8. PubMed ID: 12874704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.